Irbesartan Tablet
Product Images NDC 50228-162

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 50228-162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Irbesartan-figure-1 (Irbesartan Figure 1)

Two scatter plots with trend lines showing placebo-subtracted reductions in trough SeSBP and trough SeDBP versus irbesartan dose (mg/day). The left graph depicts reductions in systolic blood pressure, and the right graph depicts reductions in diastolic blood pressure, both as integrated analyses.*

FDA Label Image

Irbesartan-figure-2 (Irbesartan Figure 2)

A Kaplan-Meier survival curve chart depicting cumulative event rates over 60 months of follow-up. It compares Irbesartan, Amlodipine, and placebo groups regarding the primary endpoint including doubling of serum creatinine, end-stage renal disease, or all-cause mortality. The chart includes relative risk (RR) and p-values for Irbesartan versus placebo and Amlodipine.*

FDA Label Image

Irbesartan-figure-3 (Irbesartan Figure 3)

Label for Irbesartan Tablets, USP 75 mg oral tablets by ScieGen Pharmaceuticals, Inc. The label indicates 30 tablets per container with standard storage instructions and dosing guidance to see the package insert. It includes the NDC 50228-160-30 and barcode, with a note on child-resistant packaging and a green section labeled 'NO VARNISH.'*

FDA Label Image

Irbesartan-figure-4 (Irbesartan Figure 4)

Label for Irbesartan Tablets, USP, 75 mg oral tablets by ScieGen Pharmaceuticals, Inc. The label shows a count of 500 tablets, includes storage instructions, dosage reference, and a barcode. The product is prescription only with NDC 50228-160-05.*

FDA Label Image

Irbesartan-figure-5 (Irbesartan Figure 5)

Label for Irbesartan Tablets, USP 150 mg oral tablets by ScieGen Pharmaceuticals, Inc. The label states storage instructions, dosage notes, and child-resistant container requirements. The package contains 30 tablets and is Rx only. The label includes a barcode and NDC 50228-161-30.*

FDA Label Image

Irbesartan-figure-6 (Irbesartan Figure 6)

Label for Irbesartan Tablets, USP 150 mg by ScieGen Pharmaceuticals, Inc. The label states each tablet contains 150 mg of Irbesartan, with a package size of 1,000 tablets. It includes storage instructions (20°C to 25°C), a barcode, and notes this is a prescription-only medication. The label also indicates the product is dispensed in a child-resistant container.*

FDA Label Image

Irbesartan-figure-7 (Irbesartan Figure 7)

Label for Irbesartan Tablets USP 300 mg by ScieGen Pharmaceuticals, Inc. The label states each tablet contains 300 mg Irbesartan and includes storage instructions (20° to 25°C with permitted excursions), dosage directions referencing package insert, packaging size of 30 tablets, RX only, and manufacturer details. The label also displays a barcode and NDC 50228-162-30.*

FDA Label Image

Irbesartan-figure-8 (Irbesartan Figure 8)

Label for Irbesartan Tablets USP 300 mg by ScieGen Pharmaceuticals, Inc. The tablet count is 500, and the label includes storage instructions, dosage guidelines pointing to package insert, and child-resistant container requirement. The label displays the NDC code 50228-162-05 and a barcode, with lot and expiration date spaces blank.*

FDA Label Image

Irbesartan-figure-9 (Irbesartan Figure 9)

Chemical structure of Irbesartan shown as a line-angle formula with a cyclopentane ring, ketone group, and various nitrogen-containing heterocycles arranged according to the molecular structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.